NOVO NORDISK HQ Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page...
Novo Nordisk USA Disease areas Products Sustainable business Partnering & innovation Careers About us Patient help Healthcare professionals Investors News & media Contact us Disclaimer statement I do not agree I agree Warning! Ok Cancel First name* Last name*E-mail* Current location*...
Novo Nordisk Global Disease areas Science & technology Partnering Sustainable business Careers About us Our products Patients Investors Healthcare professionals News & media Contact us Disclaimer statement I do not agree I agree Warning! Ok Cancel ...
CAREERSWorking at Novo NordiskTogether, we are life-changing Our company is our people. We know that life is anything but linear. Balancing what is important at different stages of our career is never easy. That’s why we make room for diverse life situations, always putting people first. ...
“Novo Nordisk is improving the lives of people living with serious chronic diseases through innovative digital solutions. In fact, digital technologies are transforming every aspect of our business, from the way we do research and develop new medicines to how we produce and make treatments available...
Novo Nordisk Jobs & Careers - Remote, Work From Home & Flexible Featured Awards Fortune 100 Fortune's Change the World Most Ethical Companies Forbes 2000 Forbes World's Most Innovative Companies Forbes Most Sustainable Companies Great Place to Work Best Workplaces for Diversity Forbes - World's ...
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
By continuing to use and navigate this website, you are agreeing to the use of cookies. AcceptClose Show More Options Clear
In a statement on Wednesday, Novo Nordisk declined to provide production costs for Ozempic and its weight loss drug counterpart Wegovy. But the Danish drugmaker noted that it spent almost $5 billion on research and development last year, and will spend more than $6 billion ona recent deal...
Novo Nordisk plans for life after Wegovy, setting up roots in Boston to try and find its future Ryan Cross Senior Science Correspondent LEXINGTON, Mass.— The world’s second-most valuable pharma company is on the hunt for its ne...